Fursultiamin: Compound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3002119 |
| CHEMBL ID | 1740659 |
| CHEBI ID | 135636 |
| CHEBI ID | 91836 |
| SCHEMBL ID | 24003 |
| SCHEMBL ID | 24002 |
| MeSH ID | M0008902 |
| Synonym |
|---|
| AC-4505 |
| BRD-A71157293-003-03-5 |
| n-[(4-amino-2-methyl-pyrimidin-5-yl)methyl]-n-[(e)-4-hydroxy-1-methyl-2-(tetrahydrofuran-2-ylmethyldisulfanyl)but-1-enyl]formamide |
| formamide, n-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-n-[4-hydroxy-1-methyl-2-[[(tetrahydro-2-furanyl)methyl]dithio]-1-butenyl]- |
| 804-30-8 |
| alinamin f |
| thiamine tetrahydrofurfuryl disulfide |
| fursultiamine |
| n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-{(1e)-4-hydroxy-1-methyl-2-[(tetrahydrofuran-2-ylmethyl)disulfanyl]but-1-en-1-yl}formamide |
| PRESTWICK2_001007 |
| BPBIO1_001247 |
| n-((4-amino-2-methyl-5-pyrimidinyl)methyl)-n-(4-hydroxy-1-methyl-2-((tetrahydrofurfuryl)dithio)-1-butenyl)formamide |
| linamin |
| judolor |
| einecs 212-357-1 |
| formamide, n-((4-amino-2-methyl-5-pyrimidinyl)methyl)-n-(4-hydroxy-1-methyl-2-((tetrahydrofurfuryl)dithio)-1-butenyl)- |
| formamide, n-((4-amino-2-methyl-5-pyrimidinyl)methyl)-n-(4-hydroxy-1-methyl-2-(((tetrahydro-2-furanyl)methyl)dithio)-1-butenyl)- |
| fursultiamina [inn-spanish] |
| fursultiamin |
| ttfd |
| retar b1 |
| retar-b(sub 1) |
| thiamin tetrahydrofurfuryl disulfide |
| fursultiaminum [inn-latin] |
| diteftin |
| tetrahydrofurfuryl thiamine disulfide |
| fursultiamine [inn:jan] |
| brn 0052964 |
| NCGC00179291-01 |
| BSPBIO_001133 |
| PRESTWICK3_001007 |
| AB00443520 |
| n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(e)-5-hydroxy-3-(oxolan-2-ylmethyldisulfanyl)pent-2-en-2-yl]formamide |
| n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[5-hydroxy-3-(oxolan-2-ylmethyldisulfanyl)pent-2-en-2-yl]formamide |
| n-[(4-azanyl-2-methyl-pyrimidin-5-yl)methyl]-n-[(e)-5-oxidanyl-3-(oxolan-2-ylmethyldisulfanyl)pent-2-en-2-yl]methanamide |
| n-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-n-[(e)-5-hydroxy-3-(2-oxolanylmethyldisulfanyl)pent-2-en-2-yl]formamide |
| A839907 |
| NCGC00188432-01 |
| dtxcid30809568 |
| dtxsid0023084 , |
| cas-804-30-8 |
| tox21_112989 |
| JTLXCMOFVBXEKD-FOWTUZBSSA-N |
| aliaron f |
| CHEMBL1740659 |
| alinamin-f |
| AKOS015961066 |
| 05j61265px , |
| unii-05j61265px |
| fursultiaminum |
| 5-25-12-00167 (beilstein handbook reference) |
| fursultiamina |
| n-((4-amino-2-methylpyrimidin-5-yl)methyl)-n-((1e)-4-hydroxy-1-methyl-2-((tetrahydrofuran-2-ylmethyl)disulfanyl)but-1-en-1-yl)formamide |
| fursultiamine [mi] |
| fursultiamine [who-dd] |
| fursultiamine [mart.] |
| fursultiamine [inn] |
| fursultiamine [jan] |
| smr001827667 |
| MLS006010098 |
| fursutiamine |
| SCHEMBL24003 |
| SCHEMBL24002 |
| Q-201140 |
| DB08966 |
| 10238-39-8 |
| CHEBI:135636 |
| CHEBI:91836 |
| mfcd00867383 |
| CS-8111 |
| Q5509734 |
| HY-B2082 |
| n-((4-amino-2-methylpyrimidin-5-yl)methyl)-n-(5-hydroxy-3-(((tetrahydrofuran-2-yl)methyl)disulfanyl)pent-2-en-2-yl)formamide |
| (e)-n-((4-amino-2-methylpyrimidin-5-yl)methyl)-n-(5-hydroxy-3-(((tetrahydrofuran-2-yl)methyl)disulfanyl)pent-2-en-2-yl)formamide |
| AS-14765 |
| NCGC00179291-04 |
| S6614 |
| n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(2e)-5-hydroxy-3-{[(oxolan-2-yl)methyl]disulfanyl}pent-2-en-2-yl]formamide |
| EN300-21702620 |
Fursultiamine could serve as a template for the development of drug candidates that inhibit the hepcidin-ferroportin interaction.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Fursultiamine is a unique antagonist of hepcidin in vitro that could serve as a template for the development of drug candidates that inhibit the hepcidin-ferroportin interaction." | ( High-throughput screening of small molecules identifies hepcidin antagonists. Damoiseaux, R; Fung, E; Ganz, T; Hsu, J; Nemeth, E; Sugianto, P, 2013) | 1.11 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "We performed a pharmacokinetic analysis of the blood thiamin profile after oral administration of thiamin tetrahydrofurfuryl disulfide (TTFD) to healthy adults." | ( Pharmacokinetics of thiamin after oral administration of thiamin tetrahydrofurfuryl disulfide to humans. Itokawa, Y; Kitamori, N, 1993) | 0.29 |
| " Although there are many publications on the pharmacokinetic (PK) properties of thiamine-containing products, no direct comparisons between these agents ." | ( Comparative Pharmacokinetic Analysis of Thiamine and Its Phosphorylated Metabolites Administered as Multivitamin Preparations. Han, S; Hong, T; Lee, J; Lee, S; Park, G; Park, WS; Seo, Y; Youn, S, 2016) | 0.43 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The resultant mean increments in thiamine activity, measured by Lactobacillus fermenti microbiological assay after 21 months of storage, were in the range 55 to 103% of the added vitamin, indicative of high bioavailability of thiamine from this source." | ( The stability of thiamine and thiamine tetrahydrofurfuryl disulfide added to table wines. Davis, R; Jago, J; Nixon, P; Price, J, 1991) | 0.28 |
| " The use of the well absorbed thiamine alkyl disulphides for the enrichment of the most relevant Australian beverage, namely beer, is examined." | ( The attempted enrichment of beer with thiamine alkyl disulphides. Crane, S; Price, J, 1983) | 0.27 |
| " All biokinetic data demonstrated a significantly improved thiamine bioavailability from benfotiamin compared with the other preparations." | ( Comparative bioavailability of various thiamine derivatives after oral administration. Bitsch, R; Greb, A, 1998) | 0.3 |
| " Here, we tested the effect of benfotiamine, a thiamine derivative with better bioavailability than thiamine, on cognitive impairment and pathology alterations in a mouse model of Alzheimer's disease, the amyloid precursor protein/presenilin-1 transgenic mouse." | ( Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Chen, J; Dong, W; Fei, G; Gong, N; Gu, F; Pan, X; Qin, Y; Sun, X; Xu, TL; Xu, Z; Yu, M; Yu, Z; Zhao, J; Zhao, L; Zhong, C, 2010) | 0.36 |
| " We aimed to compare the PK profiles of these lipophilic thiamine derivatives and to compare the extent of the increase in bioavailability to that of naïve thiamine." | ( Comparative Pharmacokinetic Analysis of Thiamine and Its Phosphorylated Metabolites Administered as Multivitamin Preparations. Han, S; Hong, T; Lee, J; Lee, S; Park, G; Park, WS; Seo, Y; Youn, S, 2016) | 0.43 |
| " The thiamine tetrahydrofurfuryl disulfide (TTFD) is a derivative of thiamine with higher bioavailability and solubility than thiamine and has been widely applied to health maintenance and disease therapy." | ( The Effects of Thiamine Tetrahydrofurfuryl Disulfide on Physiological Adaption and Exercise Performance Improvement. Hsu, YJ; Huang, CC; Huang, HY; Huang, WC; Lee, MC; Lin, CL; Shen, SY; Su, WH, 2018) | 0.48 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| pyrimidines | Any compound having a pyrimidine as part of its structure. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 21.1360 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 24.0203 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692; AID720719 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 10.6822 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 29.8493 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 25.8592 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 8.4127 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 39.8107 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 21 (33.33) | 18.7374 |
| 1990's | 11 (17.46) | 18.2507 |
| 2000's | 13 (20.63) | 29.6817 |
| 2010's | 13 (20.63) | 24.3611 |
| 2020's | 5 (7.94) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (48.30) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 8 (12.70%) | 5.53% |
| Reviews | 1 (1.59%) | 6.00% |
| Case Studies | 11 (17.46%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 43 (68.25%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| To Study the Effect of Fursultiamine in Esophageal Squamous Cell Carcinoma Patients Who Receive Concurrent Chemoradiotherapy [NCT02423811] | Phase 2 | 20 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||